Ubc9 expression predicts chemoresistance in breast cancer

Ubiquitin-conjugating enzyme 9(Ubc9),the sole conjugating enzyme for sumoylation,regulates protein function and plays an important role in tumorigenesis.Whether Ubc9 is involved in the chemoresistance of breast cancer remains unknown.In this study,we aimed to evaluate the contribution of Ubc9 in the chemoresistance of breast cancer.Immunohistochemistry(IHC) was used to examine the expression level of Ubc9.Chi-square test,Wilcoxon test,and one-way ANOVA were applied to analyze the relationship between Ubc9 expression,clinicopathologic features,and clinical response to neoadjuvant chemotherapy.The significance of variables for survival was analyzed by the Cox proportional hazards model in a multivariate analysis.Kaplan-Meier survival curves were plotted and log-rank test was performed.The proportion of Ubc9-positive cells was higher in invasive ductal carcinoma than in normal breast tissues [(48.48 ± 17.94)% vs.(5.82 ± 2.80)%,P < 0.001].High Ubc9 expression was associated with poor differentiation(χ2 = 6.538,P = 0.038),larger tumor size(χ2 = 4.701,P = 0.030),advanced clinical stage(χ2 = 4.651,P = 0.031),lymph node metastasis(χ2 = 9.913,P = 0.010),basal-like phenotype(χ2 = 8.660,P = 0.034),and poor clinical response to neoadjuvant chemotherapy(χ2 = 11.09,P = 0.001).The expected 6-year cumulative disease-free survival rate was 87.32% in patients with low Ubc9 expression compared to 68.78% in those with high Ubc9 expression(χ2 = 4.289,P = 0.038).These data indicate that high Ubc9 expression correlates with poor response to chemotherapy and poor clinical prognosis.

Neoadjuvant Combination Chemotherapy with Pegylated Liposomal Doxorubicin and Vinorelbine for Locally Advanced Breast Cancer

OBJECTIVE In China, vinorelbine plus an anthracycline is a common neoadjuvant regimen for locally-advanced breast cancer （LABC）. Pegylated liposomal doxorubicin （PLD） is an alternate anthracycline formulation with a more favorable safety profile compared with conventional anthracyclines. METHODS In this open-label trial, 61 women with LABC received up to 6 cycles of PLD 30 mg/m2 on Day 1 and vinorelbine 25 mg/m2 on Days 1 and 8 every 21 days. Hormone receptor and/or HER2 status was not routinely available. RESULTS The overall clinical response rate （primary efficacy endpoint） was 80% （95% CI： 68%-89%）. Two patients achieved a pathological complete response （3%）, with 75% having their tumor down-staged, and 89% proceeding to tumor resection. The most frequent nonhematologic adverse events were stomatitis, fever, rash, and palmar-plantar erythrodysesthesia, with none considered serious. Grade 3 or 4 neutropenia and thrombocytopenia occurred in 10% and 2% of patients, respectively. CONCLUSION PLD plus vinorelbine demonstrated comparable efficacy to conventional anthracyclines plus vinorelbine in the neoadjuvant treatment of LABC, but may offer safety advantages.

Clinical practice guideline for breast-conserving surgery in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021

Breast-conserving surgery(BCS)with radiotherapy is the primarily agreed surgical choice for eligible patients with an early diagnosis of breast cancer.In 2019,the panel of Chinese experts assembled by the Chinese Society for Breast Surgery(CSBrS)developed a Chinese experts’consensus on BCS for early-stage breast cancer(Version 2019)with the aim of standardizing BCS in China.Subsequently,the CSBrS conducted a review of published reports and discussions between experts to determine the key clinical questions for the Clinical Practice Guideline for BCS in Patients with Early-Stage Breast Cancer.The group evaluated the relevant evidence using the grading of recommendations assessment,development,and evaluation system,and developed a Clinical Practice Guideline for BCS in Patients with Early-Stage Breast Cancer(Version 2021),with the aim of providing guidance on clinical practice to breast surgeons in China.

Development of a nomogram to predict overall survival among non-metastatic breast cancer patients in China:a retrospective multicenter study

The accurate prediction of overall survival(OS)is important in clinical decision-making for breast cancer treatment.We developed a model to predict the OS of non-metastatic breast cancer patients in China.This multicenter study included 1844 non-metastatic breast cancer patients who underwent breast cancer surgery between January 2009 and December 2011 in 3 tertiary teaching hospitals in China.Data were collected retrospectively from the database of each hospital.We used univariate and multivariate Cox proportional hazard regression analyses to screen for predictors.A nomogram was developed in the training cohort(from Sun Yatsen Memorial Hospital[SYSMH]),externally validated in 2 validation cohorts(from the First People’s Hospital of Foshan[FPHF]and Sun Yat-sen University Cancer Center(SYUCC)),and compared with CancerMath,a mathematical-based model.We used Receiver Operating Characteristic curves and calibration plots to assess the models.At median follow-ups of 65.9,68.6,and 66.2 months,the 5-year OS rates were 93.0%,86.7%,and 91.0%in the SYSMH,FPHF,and SYUCC cohorts,respectively.We identified age,T stage,lymph node status,estrogen receptor,and human epidermal growth factor receptor 2 statuses as significant prognostic factors.A nomogram was developed and externally validated in the FPHF(area under the curve=0.74)and SYUCC(area under the curve=0.77)cohorts.Calibration plots showed that the predicted OS was consistent with the actual OS.The nomogram outperformed CancerMath in our study population.In summary,we developed a nomogram to predict survival among non-metastatic breast cancer patientsin China.This nomogram is superior to the CancerMath model in Chinese populations.